These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22278973)

  • 1. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
    Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
    Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
    Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
    Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
    CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blonanserin in the treatment of schizophrenia].
    Tenjin T; Miyamoto S
    Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
    Harvey PD; Nakamura H; Miura S
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
    Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
    Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
    Tachibana M; Niitsu T; Watanabe M; Hashimoto T; Kanahara N; Ishikawa M; Iyo M
    Asian J Psychiatr; 2016 Dec; 24():28-32. PubMed ID: 27931902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K; Horiuchi F; Ueno S
    Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
    Harvey PD; Nakamura H; Murasaki M
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
    Kotani M; Enomoto T; Murai T; Nakako T; Iwamura Y; Kiyoshi A; Matsumoto K; Matsumoto A; Ikejiri M; Nakayama T; Ogi Y; Ikeda K
    Behav Brain Res; 2016 May; 305():212-7. PubMed ID: 26970575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
    Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
    Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
    Mazeh D; Zemishlani H; Barak Y; Mirecki I; Paleacu D
    Int Psychogeriatr; 2006 Sep; 18(3):429-36. PubMed ID: 16478570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.